Changes in Beneficial Ownership · 4
OnKure Therapeutics, Inc.
OKURNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-08-07
- Issuer
- OnKure Therapeutics, Inc.
- Issuer CIK
- 0001637715
- Trading symbol
- OKUR
Reporting owner 1
- Name
- Mathers Edward T
- Reporting owner CIK
- 0001328625
- Relationship
- Director
- Address
- 104 5TH AVE, 19TH FLOOR, NEW YORK, NY, 10011
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | 4.14 | 2026-08-07 | A · Form 4 | 22,350 | A | 0 | [F1] | 2036-08-06 | Class A Common Stock | 22,350 | 22,350 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.↩ 1
Signature 1
- Signed
- /s/ Zachary Bambach, attorney-in-fact
- Date
- 2026-08-11
Company context
OnKure Therapeutics (Nasdaq: OKUR) is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of vascular anomalies and cancers that are underserved by available therapies. Using a structure and computational chemistry-driven drug design platform, OnKure is committed to improving clinical outcomes for patients by building a pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of vascular anomalies and cancer. OnKure aims to become a leader in targeting PI3Kα and has multiple programs designed to enable best-in-class targeting of this important molecular target.